How Thalidomide Works Against Cancer

The clinical significance of cereblon expression in multiple myeloma

(2013) Steven R. Schuster et al.   LEUKEMIA RESEARCH

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

(2013) J. Kronke et al.   SCIENCE

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

(2013) G. Lu et al.   SCIENCE

IMWG consensus on maintenance therapy in multiple myeloma

(2012) H. Ludwig et al.   BLOOD

Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression

(2012) Ling-Hua Zhang et al.   BRITISH JOURNAL OF HAEMATOLOGY

Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma

(2012) Yuan Xiao Zhu et al.   LEUKEMIA & LYMPHOMA

Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide

(2011) Y. X. Zhu et al.   BLOOD

Identification of a Primary Target of Thalidomide Teratogenicity

(2010) T. Ito et al.   SCIENCE

How I treat multiple myeloma in younger patients

(2009) A. K. Stewart et al.   BLOOD

IRF4 addiction in multiple myeloma

(2008) Arthur L. Shaffer et al.   NATURE

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

(2008) Charles G. Mullighan et al.   NATURE